LCI40 is an orally active dual PI3K/BRD4 inhibitor (PI3Kalpha IC50 = 0.071 µM, PI3Kbeta IC50 = 0.17 µM, PI3Kgamma IC50 = 0.66 µM, PI3Kdelta IC50 = 0.072 µM, BRD4 BD1 IC50 = 0.19 µM, and BRD4 BD2 IC50 = 1.88 µM. LCI40 inhibits phosphorylation of pAKT (S473) and suppresses c-MYC levels in mantle cell lymphoma cells. LCI40 displays immunomodulatory capacity with minimal toxicity to normal mouse immune cells. LCI40 can be used for the research of mantle cell lymphoma[1].
Molekulargewicht:
388.42
Formel:
C23H20N2O4
Target-Kategorie:
Akt,c-Myc,Epigenetic Reader Domain,PI3K
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
